Literature DB >> 8172507

Functional recovery after operative treatment of femoral neck fractures in an institutionalized elderly population.

Y Folman1, R Gepstein, A Assaraf, S Liberty.   

Abstract

Agreement that hip fracture is best treated surgically stems from the fact that early mobilization of the patient reduces morbidity and mortality. This concept was tested in 54 elderly, institutionalized patients with femoral neck fractures who were operatively treated. The patients were reviewed within 12 months after being injured. Their average age was 81.2 years, and 94% of the patients were women. Seventy-five percent of the study population had neurological disease or heart disease and were thus limited in their motivation or ability to participate in a rehabilitation program. Only 16.7% of the patients regained their overall functional ability and only 12.9% returned to their pre-injury, ambulatory status. The therapeutic concept should be reviewed and the conservative approach be given serious consideration.

Entities:  

Mesh:

Year:  1994        PMID: 8172507     DOI: 10.1016/0003-9993(94)90171-6

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  9 in total

1.  Does depression, apathy or cognitive impairment reduce the benefit of inpatient rehabilitation facilities for elderly hip fracture patients?

Authors:  Eric J Lenze; Elizabeth R Skidmore; Mary Amanda Dew; Meryl A Butters; Joan C Rogers; Amy Begley; Charles F Reynolds; Michael C Munin
Journal:  Gen Hosp Psychiatry       Date:  2007 Mar-Apr       Impact factor: 3.238

2.  [Earlier postoperative mobilization with minimally invasive hip hemiarthroplasty].

Authors:  B Preininger; M Jesacher; E Fabsits; T Winkler
Journal:  Unfallchirurg       Date:  2011-04       Impact factor: 1.000

3.  Functional outcomes and mortality vary among different types of hip fractures: a function of patient characteristics.

Authors:  Roger Cornwall; Marvin S Gilbert; Kenneth J Koval; Elton Strauss; Albert L Siu
Journal:  Clin Orthop Relat Res       Date:  2004-08       Impact factor: 4.176

4.  Early functional results after hemiarthroplasty for femoral neck fracture: a randomized comparison between a minimal invasive and a conventional approach.

Authors:  Felix Renken; Svenja Renken; Andreas Paech; Michael Wenzl; Andreas Unger; Arndt P Schulz
Journal:  BMC Musculoskelet Disord       Date:  2012-08-08       Impact factor: 2.362

5.  Serum levels of 25-hydroxyvitamin D and functional outcome among postmenopausal women with hip fracture.

Authors:  Lan-Mei Liu; Shuai-Hua Wang; Chuan-Sheng Fu; Xiang-Zhen Han; Bao-Fu Wei
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

6.  Low 25(OH) D serum levels are related with hip fracture in postmenopausal women: a matched case-control study.

Authors:  Xing-Mao Fu; Shao-Guang Fan; Shu-Liang Li; Yi-Sheng Chen; Hai Wu; Yan-Long Guo
Journal:  J Transl Med       Date:  2015-12-23       Impact factor: 5.531

7.  Change in serum level of vitamin D and associated factors at early phase of bone healing among fractured adult patients at University of Gondar teaching hospital, Northwest Ethiopia: a prospective follow up study.

Authors:  Yalelet Fentaw; Haile Woldie; Solomon Mekonnen; Adino Tesfahun Tsegaye
Journal:  Nutr J       Date:  2017-09-05       Impact factor: 3.271

8.  Does a functional activity programme improve function, quality of life, and falls for residents in long term care? Cluster randomised controlled trial.

Authors:  Ngaire Kerse; Kathy Peri; Elizabeth Robinson; Tim Wilkinson; Martin von Randow; Liz Kiata; John Parsons; Nancy Latham; Matthew Parsons; Jane Willingale; Paul Brown; Bruce Arroll
Journal:  BMJ       Date:  2008-10-09

9.  Prognostic Relevance of Circulating 25OHD Fractions for Early Recovery and Survival in Patients with Hip Fracture .

Authors:  Erzsébet Toldy; Antal Salamon; Bernadette Kálmán; Katalin Ágota; Dániel Horváth; Zoltán Lőcsei
Journal:  J Clin Med       Date:  2018-08-01       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.